Novartis To File Femara Early Adjuvant NDA In Second Quarter

The company will release topline data from a pivotal study of letrozole in early adjuvant treatment of breast cancer Jan. 26. Femara sales grew 62% in 2004 to $386 mil.; Novartis expects the aromatase inhibitor will reach $1 bil. in sales by 2008.